Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model

Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model

The axis of Programmed cell death-1 receptor (PD-1) with its ligand (PD-L1) plays a critical role in colorectal cancer (CRC) in escaping immune surveillance, and blocking this axis has been found to be effective in a subset of patients. Although blocking PD-L1 has been shown to be effective in 5–10%...

Full description

Bibliographic Details
Main Authors: Rinku Dutta, Roukiah Khalil, Karthick Mayilsamy, Ryan Green, Mark Howell, Srinivas Bharadwaj, Shyam S. Mohapatra, Subhra Mohapatra
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
PD-L1
orthotopic tumor
colorectal cancer
Mithramycin-A
combination therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.706133/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.706133/full

Similar Items